Renal effect of YM435, a new dopamine D1 receptor agonist, in anesthetized dogs

The renal effects of YM435 ((-)-(S)-4-(3,4-dihydroxyphenyl)-7,8-dihydroxy -1,2,3,4-tetrahydroisoquinoline hydrochloride hydrate), a dopamine D1 receptor agonist, were investigated in anesthetized dogs. Intravenous infusion of YM435 (0.1-3 micrograms/kg per min) increased renal blood flow and decreas...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmacology 1997-03, Vol.322 (1), p.45-53
Main Authors: YATSU, T, ARAI, Y, TAKENAKA, T, TAKIZAWA, K, KASAI-NAKAGAWA, C, TAKANASHI, M, UCHIDA, W, INAGAKI, O, TANAKA, A, ASANO, M, HONDA, K
Format: Article
Language:English
Subjects:
Anesthesia
Angiotensin II - antagonists & inhibitors
Angiotensin II - pharmacology
Animals
Benzazepines - pharmacology
Biological and medical sciences
Dogs
Dopamine Agonists - pharmacology
Dopamine Antagonists - pharmacology
Dose-Response Relationship, Drug
Electric Stimulation
Female
Hemodynamics - drug effects
Infusions, Intravenous
Isoquinolines - pharmacology
Kidney - drug effects
Kidney - innervation
Kidney Diseases - physiopathology
Kidney Diseases - prevention & control
Kidney Function Tests
Male
Medical sciences
Pharmacology. Drug treatments
Platelet Activating Factor - pharmacology
Receptors, Dopamine D1 - agonists
Receptors, Dopamine D1 - antagonists & inhibitors
Renal Circulation - drug effects
Tetrahydroisoquinolines
Urinary system
Vasodilator Agents - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The renal effects of YM435 ((-)-(S)-4-(3,4-dihydroxyphenyl)-7,8-dihydroxy -1,2,3,4-tetrahydroisoquinoline hydrochloride hydrate), a dopamine D1 receptor agonist, were investigated in anesthetized dogs. Intravenous infusion of YM435 (0.1-3 micrograms/kg per min) increased renal blood flow and decreased mean blood pressure in a dose-dependent manner with little effect on heart rate. Glomerular filtration rate, urine flow and urinary sodium excretion were concomitantly increased. The renal effect of YM435 by intravenous infusion at 0.3 microgram/kg per min was completely blocked by treatment with the selective dopamine D1 receptor antagonist SCH 23390 (7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazep ine hydrochloride). Furthermore, intravenous infusion of YM435 (0.3 microgram/kg per min) reversed the angiotensin II-induced decreases in renal blood flow, glomerular filtration rate, urine flow and urinary sodium excretion, and prevented the decrease in renal blood flow, glomerular filtration rate and urine flow induced by renal nerve stimulation and platelet-activating factor (PAF). These results suggest that intravenous administration of YM435 produces renal vasodilating and diuretic/natriuretic effects by stimulation of dopamine D1 receptors, and demonstrate that YM435 can inhibit angiotensin II-, renal nerve stimulation- and PAF-induced renal dysfunction.
ISSN:0014-2999
1879-0712
DOI:10.1016/S0014-2999(96)00980-6